DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.6% – Time to Sell?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC)’s stock price was down 1.6% on Monday. The stock traded as low as $7.95 and last traded at $8.20. Approximately 185,580 shares traded hands during trading, a decline of 20% from the average daily volume of 232,278 shares. The stock had previously closed at $8.33.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DMAC. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

DiaMedica Therapeutics Price Performance

The stock has a market cap of $442.23 million, a PE ratio of -11.39 and a beta of 0.92. The firm’s 50 day moving average price is $7.09 and its two-hundred day moving average price is $6.68.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. Analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new stake in DiaMedica Therapeutics in the second quarter valued at $829,000. Squarepoint Ops LLC bought a new position in DiaMedica Therapeutics in the second quarter worth $1,023,000. Bank of America Corp DE increased its stake in shares of DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock worth $290,000 after acquiring an additional 16,446 shares in the last quarter. AWM Investment Company Inc. bought a new position in shares of DiaMedica Therapeutics during the second quarter valued at approximately $253,000. Finally, Renaissance Technologies LLC bought a new position in DiaMedica Therapeutics during the 1st quarter valued at approximately $356,000. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company’s research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options.

Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury.